Loading

Annals of Clinical Pathology

Pitfalls of Diagnosis of Extraprostatic Extension in Prostate Adenocarcinoma

Review Article | Open Access

  • 1. Department of Pathology, Brown University, USA
+ Show More - Show Less
Corresponding Authors
Ali Amin, Department of Pathology, Brown University, The Miriam Hospital, 164 Summit Ave, Providence, RI 02906, USA, Tel: 401-793-7813
Abstract

Extra prostatic extension (EPE) is of the important features to evaluate in pathological assessment of radical prostatectomy specimens. Despite the uncomplicated definition of presence of neoplastic glands outside the prostatic boundary, diagnosing EPE is not always straightforward, the main reason being absence of true capsule around prostate gland. Other confounding findings include intracapsular incision, desmoplastic reaction, intraprostatic fat, tumor displacement (pseudo invasion) and benign mimickers. This study reviews different situations obscuring the diagnosis of EPE and is the first study illustrating pseudo invasion in prostate.

Citation

Amin A (2016) Pitfalls of Diagnosis of Extraprostatic Extension in Prostate Adenocarcinoma. Ann Clin Pathol 4(6): 1086.

Keywords

•    Extra prostatic extension
•    Prostate
•    Adenocarcinoma
•    Pseudo invasion
•    Paraganglia

INTRODUCTION

Prostate adenocarcinoma (PCa) is the most common cancer in male. Radical prostatectomy (RP) is the treatment of choice for intermediate grade PCa (GS 7) as well as non - low volume, low grade (GS 6) PCa. Two most significant histological indicators of prognosis in PCa are grade and stage (assessed by Gleason Score (GS) and TNM systems respectively) that are vital for decision making in post RP management of PCa. Based on AJCC 7th edition (2003), the most significant features determining the stage are organ confinement, extra prostatic extension (EPE), seminal vesicle involvement and lymph node metastasis. Although clear guidelines have been proposed to diagnose EPE, a significant interobserver variability is present between pathologists [1]. Considering the importance of correct pathological staging, this study illustrates potential morphologic pitfalls in identification of EPE with a review of literature.

Definition of extra prostatic extension

Extra prostatic extension (EPE) is defined as presence of neoplastic glands beyond the normal boundaries of the prostate gland. Prostate gland has no true anatomical capsule [2]; a fact that confounds objective assessment of EPE. It is recommended to use an arbitrary line separating prostate gland from peri-prostatic connective tissue. Since most of the prostate is surrounded by loose connective tissue, an imaginary line separating the last thick muscle bundles of prostate tissue from the loose connective tissue and fat is considered to be the capsule, and identification of tumor infiltration through this line is considered EPE. There are exceptions to the rule in the apex and base of tumor.

I-Apex of prostate

The anterior aspect (apex) of the prostate gland has least defined boundary and causes the most controversy; [3] therefore EPE in apex should be evaluated carefully. In this region of prostate gland, skeletal muscle bundles join together with normal prostate tissue, therefore benign glands are frequently intermixed with skeletal muscle [4]. The findings may be more alarming when malignant glands are present admixed with skeletal muscle bundles. Based on current recommendations, regardless of presence or absence of benign glands in such condition, the tumor is considered organ confined as long as there is no tumor present at the margin of prostatectomy [5]. Having both benign and malignant gland at the inked margin in apical sections should be considered intra - capsular incision (vide infra) [4]. When identifying malignant glands at the inked margin at apex, the finding is considered a positive margin in an area of EPE [3,6].

II-Base of prostate

Moreover, the boundaries of prostate are irregular at the base of the prostate and around seminal vesicles. In this region, presence of tumor next to fat is essential for diagnosing EPE.

Focal vs. non-focal EPE

Several studies have demonstrated that differentiating focal and non-focal EPE has significant impact on the outcome and management of the disease; [7-9] therefore one has to report the extend of EPE in the CAP criteria. Unfortunately, there are no unified criteria for distinction of focal and non-focal EPE. The initial recommendations considered limited neoplastic glands outside prostate gland boundaries as focal EPE, [7] which makes such evaluation very subjective. More objective methods consider focal EPE as less than one high magnification field in up to 2 sections, [8] or EPE limited to one slide only [9]. The author uses the last method as it appears to be simpler, more practical and reproducible.

Intra-capsular incision

Intracapsular incision (ICI) is a rare finding that occurs when surgeon unintentionally fails to remove the entire prostate tissue, and some of the benign and malignant prostate tissue is left behind. It is most frequently identified around the neurovascular bundles, but can be seen anywhere in a RP specimen. The implications of ICI includes shortened or absence of PSA nadir and higher biochemical recurrence [10-12].

ISUP consensus recommended that any ICI is reported in the pathology report [4]. When ICI occurs in the tumor region, evaluation of EPE may not be possible. One common mistake is upstaging cases with ICI at tumor to pT3 in the absence of additional definite EPE. Studies have shown a worse prognosis for ICI compared to organ confined tumor (pT2), but better than extra prostatic excision (pT3a) [3,4,13,14]. Therefore, it is more appropriate to assign a stage pT2 (R1) in a situation where there is margin positivity in an area of ICI without additional evidence of EPE.

Margin positivity

According to AJCC 7th edition, margin status affects the outcome of RP and needs to be reported in the final stage; however there is controversy regarding what aspects of positive margin need to be reported. Some studies have shown correlation between GS at positive margin and biochemical recurrence; [15,16] but others failed to reveal any association [17]. Similarly, length of positive margin has been shown to have predictive value in biochemical recurrence in some studies [18] but not others [13].

Artifacts

There are several methods used in nerve sparing RP to avoid neural damage and yet achieve appropriate hemostasis. Occasionally, thermal and mechanical artifacts are formed because of operation and tissue processing methods that can be a source of frustration in evaluation of EPE [1]. It should be noted that prostate has very little loose connective tissue at the periphery that can be disrupted at any time during the operation or specimen handling [19]. Hong et al., identified periprostatic adipose tissue in only 48% of the RP cases in their series [20]. Simple measures like obtaining additional levels from suspicious block can usually be helpful in resolving the issue.

EPE usually forms irregular protrusion or breaching of cancer outside a neoplastic clone. In situations where artifacts compromise morphology, one should pay attention to the tumor nodule at scanning magnification. Numerous studies have shown that distance of tumor to the margin has no effect on stage or biochemical recurrence; [8,19,21,22] therefore in the absence of peripheral irregularity, a well - delineated tumor nodule can be safely considered organ confined as long as there are benign stromal cells between the tumor and periprostatic tissue.

Desmoplastic reaction

Fibrosis and desmoplastic reaction to EPE seldom happens. It blends in with the normal prostate stroma when there is extra prostatic extension in the posterior and posterolateral aspects of prostate [14]. In such events one may be able to identify dense muscle bundles of prostatic stroma to show the boundary of prostate or residual adipose tissue in the desmoplastic reaction, [14] which is not always feasible.

Benign prostate stroma is composed predominantly of smooth muscle fibers with a variable population of fibroblasts, myofibroblasts and collagen fibers [23,24]. There is increased cellular density in the transition zone compared to the peripheral zone, mostly due to excess smooth muscle fibers [25]. Unlike the benign stromal cells that arrange in short streaming fascicles and have bland nuclear features, desmoplastic stroma in prostate cancer is enriched in fibroblasts and myofibroblasts and has less smooth muscle cells showing haphazard cellular arrangement with commonly plump nuclear features, clearing and clumping of chromatin, and more prominent nucleoli [24]. Similar features may be seen in infections and inflammations of the prostate; however inflammation associated stromal changes usually surrounds prostatic glands and is associated with conspicuous acute and chronic inflammatory cells. A combination of Mallory trichrome, vimentin, actin and desmin in differentiation can help in distinction [24].

Intraprostatic fat

The most helpful finding in establishing EPE is identifying tumor cells abutting adipocytes [26]. However, one has to bear in mind that adipose tissue can be found inside prostate gland [27-31]. The frequency may show a racial variation [27] and is reported to be focal rather than diffuse in prostate gland, therefore compromising EPE diagnosis in prostate biopsies. Luckily, this finding is very rare. This situation is not much of a concern in RP cases [31]. The author has confronted misplaced adipose tissue inside a circular tract of prostate core biopsy in RP.

Tumor misplacement (pseudo invasion)

Misplacement of tissue has been reported to occur infrequently after needle sampling of various organs, including thyroid [32-35]. The misplaced tissue may be non - neoplastic; however the findings cause confusion when translocation of neoplastic tissue occurs. The most significant implication of such finding includes misinterpretation of the pseudo invasion as true invasive disease, resulting in unnecessary intervention. So far, there has been no report of any adverse effect cause by misplaced malignant tissue; therefore it is of utmost significance to distinguish between true and pseudo invasion.

Displacement is defined as inadvertent placement of prostate tissue as an inclusion in a secondary location away from the origin that is usually due to invasive procedures like obtaining needle biopsy (Figure 1). This secondary location may be inside the prostate or in periprostatic soft tissue. Displacement of benign prostate tissue and corpora amylacea is a common finding in RP specimens, but rarely one can confront displacement of neoplastic tissue (high grade PIN or adenocarcinoma). When no sign of malignancy is present, presence of inclusion is of no concern. But when adenocarcinoma is displaced, differentiation with EPE is necessary. The features helpful in identification of benign displacement include identification of benign glands or corpora amylacea in the vicinity, lack of continuation between the displaced tissue and tumor nodule and association of inclusion with hemosiderin laden macrophages, chronic inflammation, fat necrosis or multinucleated giant cells (evidence of prior biopsy tract). In addition, EPE often causes a desmoplastic reaction and is usually found ipsilateral to the dominant tumor nodule. The author has confronted a case where the area of biopsy needle tract showed fat necrosis inside prostate, mimicking extraprostatic adipose tissue.

Similar argument holds when confronting displaced PCa in lymphovascular spaces, both inside and outside the prostate gland. EPE may be present in the form of lymphovascular invasion (LVI). Kryvenko et al., reviewed the differentiating features of true LVI with benign mimickers and found that benign prostate epithelium and corpora amylacea can be found inside a true vascular lumen in radical prostatectomy specimens, and should be considered benign [36]. In the presence of such findings, noticing malignant glands inside vascular lumen may represent a displacement process.

Paraganglia

Paraganglia can be identified in 8% of radical prostatectomies, [37,38] and with less frequency in TURP and prostate biopsies [39]. Because of morphologic appearance, paraganglia can be a mimicker of high Gleason grade prostate adenocarcinoma both inside and outside the prostate tissue, especially when there is thermal artifact or the cancer has foamy cell features [40]. It is usually identified in the posterior and lateral aspects of periprostatic connective tissue in association with nerve bundles and vascular channels (Figure 2). Most common morphologic patterns are individual or small clusters of neuroendocrine cells with abundant clear to finely granular cytoplasms without nuclear atypia or conspicuous nucleoli. Ganglion cells can also be a mimicker of prostate carcinoma; they usually are identified inside nerve bundles and appear as large polygonal cells with abundant eosinophilic or amphophilic cytoplasms, rounded nuclei with a single prominent nucleolus.

Rarely, paraganglia can appear forming acinar structures (Figure 2D), which may be mistaken for EPE. When in doubt, positive immunostaining for S100 in paraganglia and chromogranin A and synaptophysin in ganglion cells as well as negative staining for prostate markers like PSA, AMACR, PSMA and Prostein can help rectify the issue.

Radial distance of EPE

Recent studies have looked into sub staging of prostate cancers with EPE (pT3a). Several studies have looked into features that affect outcome in prostate carcinoma, features like extent of EPE (Table 1) (41-47). In their study, Sung et al compared various protocols in reporting the EPE and found that only implementing radial distance of EPE from prostatic capsule using an ocular micrometer can help predict biochemical recurrence. [46] van Veggel et al., showed that the best discriminatory power belonged to dividing EPE into focal and non-focal subcategories, but in an effort to identify a more objective assessment of EPE, the authors found that maximal radial distance of 1 high power field (HPF) (equal to 0.6mm) can be used as a strong predictor of biochemical recurrence [47]. Additional studies are needed to attest the usefulness of radial distance measurement in the follow up of PCa.

Investigations have revealed potential serum markers for diagnosis of EPE preoperatively. Lee et al., showed that serum hormone binding globulin (SHBG) level is an independent predictive factor for extra prostatic extension of tumor in patients with clinically localized prostate cancer. [48] SHBG is a circulating glycoprotein that has great affinity for testosterone. Absence of diurnal variation like testosterone level in serum makes SHBG a better and more reliable surrogate marker for assessing systemic androgenicity. The findings however have not been validated. Immunohistochemical studies (i.e. P53) has been shown to correspond to malignant behavior but no use in EPE detection was identified [49].

Table 1: Review of literature on extra prostatic extension in radical prostatectomy.

  Davis et al. (1999) Sohayda et al. (2000) Teh et al. (2003) Chao et al. (2006) Schwartz et al. (2007) Sung et al. (2007) vanVeggel et al. (2011)
Patient number 376 265 712 371 404 83 134
EPE (%) 105 (28) 92 (35) 299 (42) 121 (33) 121 (30) 83 (100) 134 (100)
Preop PSA in EPE + cases Mean:17.9 Median:7.4 Mean:13.73 Mean:14.5 Median:8.5 n/a n/a
EPE distance (mm) Median (0.5); mean (0.8mm) Median (1.1mm) Median (2.0mm) Median (2.4mm); mean (2.3mm) Median (0.6mm); mean (0.9mm) Median (0.75mm); mean (1.06mm) Median (1.0mm)
EPE range (mm) 0.04-4.4 0.1-10.0 0.5-12.0 0.05-7.0 0.0-5.7 0.08-6.0 n/a
Abbreviations: EPE: Extra Prostatic Extension; Preop: Preoperative; mm: Millimeter; n/a: Not Available

 

CONCLUSION

Identification of EPE is of significant importance in the staging and management of PCa, and there are well-established criteria for diagnosis of EPE. Pathologists should be familiar with the morphological aspects as well as pitfalls of diagnosing EPE. Additional studies are needed to determine the extent of information in reporting EPE.

REFERENCES

1. Evans AJ, Henry PC, Van der Kwast TH, Tkachuk DC, Watson K, Lockwood GA, et al. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol. 2008; 32: 1503- 1512.

2. Ayala AG, Ro JY, Babaian R, Troncoso P, Grignon DJ. The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol. 1989; 13: 21-27.

3. Chuang AY, Nielsen ME, Hernandez DJ, Walsh PC, Epstein JI. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol. 2007; 178: 1306-1310.

4. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011; 24: 48-57.

5. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011; 24: 26-38.

6. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005; 216: 34-63.

7. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol. 1993; 150: 135-141.

8. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998; 29: 856-862.

9. Chan SM, Garcia FJ, Chin JL, Moussa M, Gabril MY. The clinical significance of in-depth pathological assessment of extraprostatic extension and margin status in radical prostatectomies for prostate cancer. Prostate Cancer Prostatic Dis. 2011; 14: 307-312.

10. Adnan Simsir, Cag Cal, Rashad Mammadov, Ibrahim Cureklibatir, Bulent Semerci, Gurhan Gunaydin. Biochemical recurrence after radical prostatectomy: is the disease or the surgeon to blame? Int Braz J Urol. 2011; 37: 328-335.

11. Kwak KW, Lee HM, Choi HY. Impact of capsular incision on biochemical recurrence after radical perineal prostatectomy. Prostate Cancer Prostatic Dis. 2010; 13: 28-33.

12. Shuford MD, Cookson MS, Chang SS, Shintani AK, Tsiatis A, Smith JA Jr, et al. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004; 172: 119-123.

13. Warner JN, Nunez RN, Mmeje CO, Colby TV, Ferrigni RG, Humphreys MR, et al. Impact of margin status at 37 months after robot assisted radical prostatectomy. Can J Urol. 2011; 18: 6043-6049.

14. Chuang AY, Epstein JI. Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls. Am J Surg Pathol. 2008; 32: 1201-1206.

15. Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, et al. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int. 2012; 109: 1794-1800.

16. Brimo F, Partin AW, Epstein JI. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology. 2010; 76: 1206-1209.

17. Marks RA, Koch MO, Lopez-Beltran A, Montironi R, Juliar BE, Cheng L. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol. 2007; 38: 1207-1211.

18. Cao D, Humphrey PA, Gao F, Tao Y, Kibel AS. Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. Urology. 2011; 77: 1409-1414.

19. Montironi R, Cheng L, Mazzucchelli R, Lopez-Beltran A. Pathological definition and difficulties in assessing positive margins in radical prostatectomy specimens. BJU Int. 2009; 103: 286-288.

20. Hong H, Koch MO, Foster RS, Bihrle R, Gardner TA, Fyffe J, et al. Anatomic distribution of periprostatic adipose tissue: a mapping study of 100 radical prostatectomy specimens. Cancer. 2003; 97: 1639-1643.

21. Epstein JI, Sauvageot J. Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression? J Urol. 1997; 157: 241-243.

22. Emerson RE, Koch MO, Daggy JK, Cheng L. Closest distance between tumor and resection margin in radical prostatectomy specimens: lack of prognostic significance. Am J Surg Pathol. 2005; 29: 225-229.

23. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR, et al. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002; 62: 3298-3307.

24. Tomas D, Kruslin B. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate. 2004; 61: 324-331.

25. Jonathan I. Epstein, Antonio L. Cubilla, Peter A. Humphrey. The normal prostate gland. In Tumors of the Prostate Gland, Seminal Vesicles, Penis and Scrotum. AFIP Atlas of Tumor Pathology 4th series. ARP Press. 2011; 14: 15-16.

26. Sung MT, Eble JN, Cheng L. Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma. Pathology. 2006; 38: 309-311.

27. Cohen RJ, Stables S. Intraprostatic fat. Hum Pathol. 1998; 29: 424-425.

28. Billis A. Intraprostatic fat: does it exist? Hum Pathol. 2004; 35: 525.

29. Nazeer T, Kee KH, Ro JY, Jennings TA, Ross J, Mian BM, et al. Intraprostatic adipose tissue: a study of 427 whole mount radical prostatectomy specimens. Hum Pathol. 2009; 40: 538-541.

30. Joshi A, Shah V, Varma M. Intraprostatic fat in a prostatic needle biopsy: a case report and review of the literature. Histopathology. 2009; 54: 912-913.

31. Nopajaroonsri C. Intraprostatic fat. Hum Pathol. 1998; 29: 887.

32. Tavassoli FA, Pestaner JP. Pseudoinvasion in intraductal carcinoma. Mod Pathol. 1995; 8: 380-383.

33. Vercelli-Retta J, Almeida E, Ardao G, Paseyro AM, Pedreira G, Morelli R, et al. Capsular pseudo invasion after fine-needle aspiration of follicular adenomas of the thyroid. Diagn Cytopathol. 1997; 17: 295-297.

34. Pandit AA, Phulpagar MD. Worrisome histologic alterations following fine needle aspiration of the thyroid. Acta Cytol. 2001; 45: 173-179.

35. Chebib I, Opher E, Richardson ME. Vascular and capsular pseudoinvasion in thyroid neoplasms. Int J Surg Pathol. 2009; 17: 449-451.

36. Kryvenko ON, Epstein JI. Histologic criteria and pitfalls in the diagnosis of lymphovascular invasion in radical prostatectomy specimens. Am J Surg Pathol. 2012; 36: 1865-1873.

37. Ostrowski ML, Wheeler TM. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma. Am J Surg Pathol. 1994; 18: 412-420.

38. Maniar KP, Unger PD, Samadi DB, Xiao GQ. Incidental prostatic paraganglia in radical prostatectomy specimens: a diagnostic pitfall. Int J Surg Pathol. 2011; 19: 772-774.

39. Kawabata K. Paraganglion of the prostate in a needle biopsy: a potential diagnostic pitfall. Arch Pathol Lab Med. 1997; 121: 515-516.

40. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol. 1996; 20: 419-426.

41. Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, Bostwick DG, Herman MG, et al. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: Is extraprostatic seed placement necessary? Tech Urol. 2000; 6: 70-77.

42. Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology. 2000; 55: 382-386.

43. Teh BS, Bastasch MD, Wheeler TM, Mai WY, Frolov A, Uhl BM, et al. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys. 2003; 56: 184-191.

44. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys. 2006; 65: 999-1007.

45. Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, et al. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys. 2007; 69: 411-418.

46. Sung MT, Lin H, Koch MO, Davidson DD, Cheng L. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol. 2007; 31: 311-318.

47. van Veggel BA, van Oort IM, Witjes JA, Kiemeney LA, Hulsbergen-van de Kaa CA. Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy. Histopathology. 2011; 59: 692-702.

48.

49. Lee SE, Chung JS, Han BK, Park CS, Moon KH, Byun SS, et al. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer. Eur Urol. 2008; 54: 1324-1332.

50. Saidi S, Georgiev V, Stavridis S, Penev M, Stankov O, Dohcev S, et al. Evaluation of the value of p53 protein expression in the extra-capsular extension of prostate cancer. Prilozi. 2011; 32: 213-220.

Received : 27 Jun 2016
Accepted : 10 Jul 2016
Published : 11 Jul 2016
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X